Sudeep Pharma Share Price Forecast to 2030

The Sudeep Pharma share price forecast for the next 3 years is a question on many investors' minds as the stock trades at Rs 856.25, within a 52 week range of Rs 524.00 to Rs 908.00. This article lays out a scenario based Sudeep Pharma share price outlook for 2027, 2028 and 2030, built on the company's fundamentals, sector trends and the key risks that could change the trajectory. Rather than a single number, the focus here is on the range of outcomes and the assumptions behind each one.

Click Here – Get Free Investment Predictions

Sudeep Pharma Company Overview

Sudeep Pharma manufactures pharmaceutical formulations and active pharmaceutical ingredients for domestic and export markets, having listed in 2025. Understanding the business model is the first step in framing any credible Sudeep Pharma share price forecast, because the durability of earnings ultimately decides where the stock trades.

Company	Sudeep Pharma
NSE Ticker	SUDEEPPHRM
CMP	Rs 856.25
52 Week High	Rs 908.00
52 Week Low	Rs 524.00
Market Cap	Rs 9671. Cr
Stock PE	55.9
Book Value	₹ 78.2
ROE	25.2 %
ROCE	28.2 %
Dividend Yield	0.18 %

Where Does Sudeep Pharma Share Price Stand Today?

The stock currently trades at Rs 856.25, within a 52 week range of Rs 524.00 to Rs 908.00. For anyone building a Sudeep Pharma share price forecast, this means the valuation starting point is a P/E of 55.9. How the broader Nifty 50 index trades over this period will also influence the multiple investors are willing to assign to the stock.

At the current price, Sudeep Pharma commands a market capitalisation of Rs 9671. Cr and trades at a price to earnings multiple of 55.9. The company generates a return on equity of 25.2 % and a return on capital employed of 28.2 %. These numbers anchor the Sudeep Pharma share price forecast scenarios that follow.

Sudeep Pharma Share Price Forecast: Key Growth Drivers for the Next 3 Years

The primary growth catalyst for Sudeep Pharma is rising domestic and export demand for its pharma formulation and API portfolio. This driver is anchored in structural trends within the Pharmaceuticals sector.

Earnings Trajectory and Return Ratios

Stock prices ultimately follow earnings. The pace at which profits compound over FY27 to FY30 will be the single biggest determinant of the Sudeep Pharma share price forecast actually playing out. Consistent earnings delivery tends to expand valuation multiples, while misses compress them quickly.

Pharmaceuticals Sector Dynamics

Sector trends are a second key driver. Within the space, investors often benchmark Sudeep Pharma against peers such as Supriya Lifescience, NGL Fine-Chem, Gufic Biosciences on growth and valuations before forming a view on the Sudeep Pharma share price forecast for the next 3 years.

Balance Sheet and Debt Management

the ability to manage financial leverage will directly influence the Sudeep Pharma share price forecast. Companies that reduce debt or fund growth without diluting equity tend to see stronger share price appreciation.

Macro and Policy Environment

Interest rate cycles, currency movements and sector-specific policy changes will also shape the Sudeep Pharma share price forecast over the 2027 to 2030 horizon. These are harder to predict but need to be monitored closely.

Consult a SEBI Registered Investment Advisor Before Acting on Any Forecast

Key Risks to the Sudeep Pharma Share Price Forecast

The Sudeep Pharma share price forecast could be materially impacted by the company is newly listed with a shorter standalone track record, and regulatory compliance is a key risk. These risks are not unique to Sudeep Pharma but the degree of impact depends on the company's specific exposure and management quality.

Sudeep Pharma Share Price Forecast: 3-Year Scenario Table

The following indicative scenario analysis is illustrative only and does not constitute a research-grade price target. Actual outcomes will depend on company performance, sector dynamics, and macroeconomic conditions.

Scenario	3-Year Indicative Range	Key Assumptions
Bull Case	Rs 1,541	Strong execution, sector tailwinds materialise, margin expansion via operating leverage
Base Case	Rs 1,156	Steady growth broadly in line with sector, manageable cost pressures, stable demand conditions
Bear Case	Rs 642.19	Demand slowdown, margin compression from rising costs, or sector-specific headwinds materialise

These ranges are not investment advice. The bull case assumes key growth drivers materialise fully, while the bear case reflects meaningful headwinds. The base case represents a moderate, sector-average outcome.

Download the Univest iOS App or Univest Android App to track Sudeep Pharma share price and get real-time alerts.

Should You Invest in Sudeep Pharma?

Any investment in Sudeep Pharma must be evaluated against your own risk profile, investment horizon, and portfolio composition. The Sudeep Pharma share price forecast outlined here is scenario-based and not a guaranteed outcome. Key considerations are the growth drivers (rising domestic and export demand for its pharma formulation and API portfolio), the risks (the company is newly listed with a shorter standalone track record, and regulato), and how those interact with your overall portfolio strategy.

Retail investors are always advised to consult a SEBI-registered investment advisor before taking any position. The Pharmaceuticals index provides a useful benchmark for comparing Sudeep Pharma share price performance against the broader sector.

Conclusion

The Sudeep Pharma share price forecast for the next 3 years ranges from Rs 642.19 in the bear case to Rs 1,541 in the bull case, with a base case around Rs 1,156. The primary driver is rising domestic and export demand for its pharma formulation and API portfolio, while the main risk is the company is newly listed with a shorter standalone track record, and regulato. Investors should track quarterly results, balance sheet trends, and sector developments to refine their view as the forecast horizon approaches.

This article is for informational purposes only. Consult a SEBI-registered advisor before investing.

Frequently Asked Questions on Sudeep Pharma Share Price Forecast

What is the Sudeep Pharma share price forecast for the next 3 years?

Ans. The Sudeep Pharma share price forecast for the next 3 years is scenario based rather than a single number. By 2030, the illustrative range spans Rs 642.19 in the bear case to Rs 1,541 in the bull case, with a base case near Rs 1,156, depending on earnings delivery and market conditions.

What is the Sudeep Pharma share price forecast for 2027?

Ans. For 2027, the scenario range works out to Rs 813.44 to Rs 1,113, with a base case around Rs 941.88. This assumes compounding on the current price of Rs 856.25 and is illustrative, not a guaranteed outcome.

What is the Sudeep Pharma share price forecast for 2028?

Ans. The 2028 scenario range is Rs 727.81 to Rs 1,284, with the base case near Rs 1,028. Actual levels will depend on earnings growth, sector trends and overall market valuations at the time.

What is the current share price of Sudeep Pharma?

Ans. Sudeep Pharma currently trades at around Rs 856.25 on the NSE, within a 52 week range of Rs 524.00 to Rs 908.00. Prices change continuously during market hours, so check live quotes before acting.

Is Sudeep Pharma a good stock for the long term?

Ans. Sudeep Pharma has a long term story built on rising domestic and export demand for its pharma formulation and API portfolio, but it also carries risks since the company is newly listed with a shorter standalone track record, and regulato. Long term suitability depends on your risk profile and portfolio, so consult a SEBI registered investment advisor before investing.

What is the Sudeep Pharma share price outlook for 2030?

Ans. The Sudeep Pharma share price outlook for 2030 spans Rs 642.19 to Rs 1,541 across bear and bull scenarios. Where the stock actually lands will be driven by profit growth, valuation multiples and macro conditions closer to that date.

What are the key risks to the Sudeep Pharma share price forecast?

Ans. The main risks are the company is newly listed with a shorter standalone track record, and regulatory compliance is a k. Any of these can push the stock below the base case scenario discussed in this article.